Drugs / Enoblituzumab
Trials 11
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-07-08 | MacroGenics | Results MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer macrogenics.com ↗
The decision to discontinue the study was based on an internal review of safety data, which included the occurrence of seven fatalities potentially associated with hemorrhagic events in both arms of the study (of 62 total patients treated). |
| 2018-11-09 | MacroGenics | Results MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting macrogenics.com ↗
who were PD-L1 negative (i.e., PD-L1<1%), 5 of 14 (35.7%) had confirmed PRs. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enoblituzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02381314 ↗ |
| Known as | MGA271 | “Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer” NCT02381314 ↗ |
| Modality | Monoclonal antibody | “Fc-optimized, humanized monoclonal antibody” NCT01391143 ↗ |
| Route | Intravenous | “given by intravenous (IV) infusion” NCT01391143 ↗ |
| Target | CD276 | “B7-H3 (CD276) is a member of the B7 family of cell surface molecules” PMID 35414591 ↗ Apr 2022 |